BRPI0417585A - composição pregabalina - Google Patents

composição pregabalina

Info

Publication number
BRPI0417585A
BRPI0417585A BRPI0417585-9A BRPI0417585A BRPI0417585A BR PI0417585 A BRPI0417585 A BR PI0417585A BR PI0417585 A BRPI0417585 A BR PI0417585A BR PI0417585 A BRPI0417585 A BR PI0417585A
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
liquid
pregabalin
pregabalin composition
Prior art date
Application number
BRPI0417585-9A
Other languages
English (en)
Inventor
Michael Schneider
Hans Richard Meyer-Wonnay
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34486238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0417585A publication Critical patent/BRPI0417585A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO PREGABALINA". é descrita uma composição farmacêutica aquosa administrável oralmente, quimicamente e fisicamente estável contendo pregabalina. A composição líquida inclui pelo menos um conservante, pelo menos um agente mascarador de sabor, e opcionalmente um agente controlador da viscosidade. A composição farmacêutica líquida tem um pH de pelo menos 5.5, mas não maior que 7.0.
BRPI0417585-9A 2003-12-18 2004-12-06 composição pregabalina BRPI0417585A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03029117A EP1543831A1 (en) 2003-12-18 2003-12-18 Pregabalin composition
PCT/IB2004/004029 WO2005063229A1 (en) 2003-12-18 2004-12-06 Pregabalin composition

Publications (1)

Publication Number Publication Date
BRPI0417585A true BRPI0417585A (pt) 2007-03-13

Family

ID=34486238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417585-9A BRPI0417585A (pt) 2003-12-18 2004-12-06 composição pregabalina

Country Status (17)

Country Link
US (1) US20050171203A1 (pt)
EP (2) EP1543831A1 (pt)
JP (1) JP2007514728A (pt)
KR (1) KR100841893B1 (pt)
CN (1) CN1893938A (pt)
AU (1) AU2004308747A1 (pt)
BR (1) BRPI0417585A (pt)
CA (1) CA2549599A1 (pt)
IL (1) IL176129A0 (pt)
MX (1) MXPA06006811A (pt)
MY (1) MY143561A (pt)
NO (1) NO20063178L (pt)
RU (1) RU2352333C2 (pt)
SG (2) SG143257A1 (pt)
TW (1) TWI279230B (pt)
WO (1) WO2005063229A1 (pt)
ZA (1) ZA200604656B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
EA020558B1 (ru) * 2012-03-20 2014-12-30 ООО "Эн.Си. ФАРМ" Фармацевтический состав, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, нейрометаболической, противоишемической активностью (варианты)
US9937153B2 (en) 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin
GR1009462B (el) * 2017-10-05 2019-02-15 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση
CN107998074A (zh) * 2017-12-13 2018-05-08 广州大光制药有限公司 普瑞巴林口服溶液及其制备方法
CN110693820A (zh) * 2018-07-10 2020-01-17 北京万全德众医药生物技术有限公司 普瑞巴林口服溶液及其制备方法
US11738020B2 (en) 2018-08-18 2023-08-29 Ftf Pharma Private Limited Stable liquid vigabatrin pharmaceutical composition for oral dosage
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
CN112107537A (zh) * 2019-06-19 2020-12-22 北京万全德众医药生物技术有限公司 一种普瑞巴林口服溶液及其制备方法
CN111855828B (zh) * 2020-02-28 2022-07-01 中国人民解放军军事科学院军事医学研究院 一种同时测定普瑞巴林以及羟苯酯类抑菌剂含量的方法
WO2022157525A1 (en) 2021-01-22 2022-07-28 Egis Gyógyszergyár Zrt. Topical formulation containing modified phospholipid compounds
HU231397B1 (hu) 2021-01-22 2023-06-28 Egis Gyógyszergyár Zrt. Pregabalint tartalmazó topikális gyógyszerkészítmény
CN113616591B (zh) * 2021-09-03 2023-05-23 贝克诺顿(浙江)制药有限公司 一种普瑞巴林口服溶液及制备方法
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
GB2624861A (en) 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
CN116172951A (zh) * 2023-03-08 2023-05-30 杭州润宠归美生物科技有限公司 一种宠物用普瑞巴林药物组合物及其制备方法和应用
GB2639602A (en) 2024-03-19 2025-10-01 Novumgen Ltd An orodispersible tablet of pregabalin and its process of preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
BR9911421A (pt) * 1998-06-22 2001-03-27 American Biogenetic Sciences Uso de análogo do ácido valpróico para o tratamento e prevenção da enxaqueca e doenças emocionais
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
BRPI0107863B8 (pt) * 2000-01-27 2017-04-25 Warner-Lambert Company método para preparar um derivado do ácido (s)-3- ciano-5-metilhexanoico, composto intermediário, seu método de preparação e método para preparar a pregabalina
DE60213592T2 (de) * 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof

Also Published As

Publication number Publication date
MY143561A (en) 2011-05-31
KR100841893B1 (ko) 2008-06-26
EP1722773A1 (en) 2006-11-22
US20050171203A1 (en) 2005-08-04
TW200520751A (en) 2005-07-01
RU2352333C2 (ru) 2009-04-20
MXPA06006811A (es) 2006-08-23
SG136119A1 (en) 2007-10-29
IL176129A0 (en) 2006-10-05
JP2007514728A (ja) 2007-06-07
AU2004308747A1 (en) 2005-07-14
WO2005063229A1 (en) 2005-07-14
CA2549599A1 (en) 2005-07-14
CN1893938A (zh) 2007-01-10
RU2006120946A (ru) 2008-01-27
SG143257A1 (en) 2008-06-27
EP1543831A1 (en) 2005-06-22
KR20060103336A (ko) 2006-09-28
NO20063178L (no) 2006-06-19
ZA200604656B (en) 2007-10-31
TWI279230B (en) 2007-04-21

Similar Documents

Publication Publication Date Title
BRPI0417585A (pt) composição pregabalina
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
BRPI0409342A (pt) pelìcula de gel termorreversìvel homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e para fabricar cápsulas moles contendo as pelìculas de gel, e, forma sólida
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
KR920019342A (ko) 골질환 치료제
BRPI9906372B8 (pt) composição farmaceutica aquosa para aplicação na mucosa
CO5700797A2 (es) Composicion de farmaco conjugado
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
TR200401906T4 (tr) Kendini emülsifiye ilaç sistemi, yağ ajanı seçime bağlıdır.
AR027748A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
BR0312782A (pt) Composição para o tratamento de manchas
BR0114272A (pt) Formulação farmacêutica de liberação prolongada independente da força iÈnica
ATE482003T1 (de) Kosmetische zubereitung mit wachskomponente, filmbildner und gelkomponente
BR0308710A (pt) conjugados poliméricos antimicrobianos
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada
BR0211245A (pt) Alimento contendo proteìna compreendendo uma enzima de ligação cruzada e um hidrocolóide
BR9913066A (pt) Utilização de pelo menos de um composto apresentando uma viscosidade de alongamento superior ou igual a duas vezes a da água e uma viscosidade de fluxo inferior ou igual a seis vezes a da água
BR0108405A (pt) Agente de ativação de célula
BRPI0611526A2 (pt) composição tópica contendo gelatina
CY1110841T1 (el) Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4)
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.
ECSP034553A (es) 3,4-DIHIDROPIRIDO (1,2-a)PIRIMIDINAS SUSTITUIDAS
BR0112787A (pt) Composições farmacêuticas contendo tobramicina e goma de xantano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.